AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00570375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg, PO, QD beginning day 1 week 1. Patients will receive treatment for 16 weeks as long as there is no evidence of disease progression. In no response is noted after 16 weeks of treatment, patients will be taken off the study. Patients achieving response (HI, CR, or PR) will continue on treatment until evidence of disease progression or relapse.
Study NCT02770911 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: without Dog Ear group
Description: a modified double-stapling technique with eliminating the dogears in laparoscopic anterior resection
Study NCT02770911 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: with Dog Ear group
Description: a traditional double-stapling technique without eliminating the dogears in laparoscopic anterior resection
Study NCT02570347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-amoxiclav
Description: Injection Co-amoxiclav 1.2 g intravenously q8h for a minimum of 48-72 hours; switched to oral Co-amoxiclav 625 mg b.i.d. when clinically appropriate.
Study NCT02570347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Co-amoxiclav
Description: Injection Co-amoxiclav 1.2 g intravenously q8h for a minimum of 48-72 hours; switched to oral Co-amoxiclav 625 mg b.i.d. when clinically appropriate.
Study NCT02570347 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus toxoid
Description: Injection Tetanus toxoid 0.5 ml intramuscularly Stat
Study NCT02570347 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus toxoid
Description: Injection Tetanus toxoid 0.5 ml intramuscularly Stat
Study NCT00529711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic lactate
Description: Solution given parenterally as follows:~Intraoperative 3 ml./kg BW for 15 minutes at beginning of surgery; During surgery 1.5 ml/kg BW/hour; Second loading 1.5 ml/kg BW for 15 minutes after protamin administration; Post-operative 1 ml/kg BW/hour for 12 hours.
Study NCT00529711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's lactate
Description: Solution given parenterally as follows:~Intraoperative 3 ml./kg BW for 15 minutes at beginning of surgery; During surgery 1.5 ml/kg BW/hour; Second loading 1.5 ml/kg BW for 15 minutes after protamin administration; Post-operative 1 ml/kg BW/hour for 12 hours.
Study NCT03729401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor Monotherapy: Ticagrelor 60 mg twice daily
Description: Ticagrelor monotherapy
Study NCT03434639 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Spectroscopic gut permeability test
Description: The spectroscopic gut permeability test first involves patients receiving an oral dose of one or more fluorescent dyes. A wearable sensor will then be attached to the patients' skin and this will be used to monitor the leakage of the fluorescent dyes from the intestine into the blood stream in a non-invasive manner. In this way, a measure of the permeability of the intestine will be obtained.~Note that patients in Group 1 (ophthalmology patients) will not receive oral doses of contrast agents. Instead, the wearable sensor will simply be used to detect the presence of fluorescent dyes that were administered intravenously as part of planned ophthalmic procedures.~Complete details of the spectroscopic gut permeability test can be found in the attached protocol.
Study NCT03744442 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dignity Therapy (DT) module
Description: psychotherapeutic intervention asking patients about their most important achievements, roles and other important aspects of life; two structured sessions of 60 minutes conducted by a trained therapist
Study NCT03729401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Personalized Therapy Arm: Aspirin 81 mg or Ticagrelor 60mg twice daily or Clopidogrel 75 mg once daily
Description: Personalized therapy based on risk score and genotyping
Study NCT03744442 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CALM Therapy module
Description: supportive-expressive psychotherapy aiming to help (1) manage the disease, symptom and treatment, and communicate with healthcare providers, to (2) adjust to changes in self-concept, personal relationships, and support needs, to (3) find a sense of meaning and purpose in life, and to (4) prepare for the future, sustain hope, and face the end of life; two structured sessions of 60 minutes conducted by a trained therapist
Study NCT03744442 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-based interventions module
Description: Mind-body techniques reducing existential and spiritual distress and dealing with common experiences related to life-limiting diseases, including loss of control, uncertainty about the future; two structured sessions of 60 minutes conducted by a trained therapist
Study NCT03920085 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OneTouch Verio
Description: OneTouch Verio Blood Glucose Monitoring System.
Study NCT03920085 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OneTouch Select Plus
Description: OneTouch Select Plus Blood Glucose Monitoring System.
Study NCT03920085 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OneTouch Ultra
Description: OneTouch Ultra Blood Glucose Monitoring System.
Study NCT00567567 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous peripheral blood stem cell transplant
Study NCT05237726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin 40 mg q24 hours
Description: Severely burn injuries (BSA≥20%) will be assigned to 3 modality regimens of pharmacological VTE prophylaxis: Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hours.
Study NCT05237726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin 30 mg q12 hours
Description: Severely burn injuries (BSA≥20%) will be assigned to 3 modality regimens of pharmacological VTE prophylaxis: Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hours.
Study NCT05237726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin 5000 U q8 hours
Description: Severely burn injuries (BSA≥20%) will be assigned to 3 modality regimens of pharmacological VTE prophylaxis: Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hours.
Study NCT00567567 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous peripheral blood stem cell transplant
Study NCT00567567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study NCT00567567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT00567567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV
Study NCT00567567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT00567567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV
Study NCT00567567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT00567567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT00567567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT00567567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV
Study NCT00567567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT00567567 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT
Study NCT00567567 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT
Study NCT00567567 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: Given IV or SC
Study NCT00567567 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given IV or SC
Study NCT00567567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin
Description: Given orally
Study NCT00567567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Given orally
Study NCT00567567 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00567567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00567567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Given IV
Study NCT00567567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT00567567 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo autologous peripheral blood stem cell transplant
Study NCT00567567 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo autologous peripheral blood stem cell transplant
Study NCT00567567 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00567567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00567567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV
Study NCT00567567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan Hydrochloride
Description: Given IV
Study NCT00567567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV
Study NCT00567567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate Liposome
Description: Given IV
Study NCT00567567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate Liposome
Description: Given IV
Study NCT03433677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered by CSII
Study NCT03433677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Description: Administered by CSII
Study NCT00750295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBR759
Description: Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
Study NCT03585010 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Parenting for Anxious Childhood Emotions
Description: 12 sessions with parents
Study NCT03585010 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Educational Support
Description: 12 sessions with parents
Study NCT03585010 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioral Therapy
Description: 12 sessions with child
Study NCT00325689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine or Risperidone + Aripiprazole
Description: Tablets, Oral, Quetiapine 400-800 mg/day or Risperidone (4-8 mg/day) + Aripiprazole 2-15 mg/day, Flexible, 16 weeks.
Study NCT00325689 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Quetiapine or Risperidone + placebo
Description: Tablets, Oral, Quetiapine 400-800 mg/day or Risperidone (4-8 mg/day) + Placebo, Flexible, 16 weeks.
Study NCT00974818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC)
Description: Patients randomized to this group will receive six weekly cycles of 40 mg of intravesical MMC (dissolved in a total volume of 20 mL sterile water). Patients will receive three weekly cycles of 40 mg of intravesical MMC (dissolved in a total volume of 20 mL sterile water) 3, 6, 12, 18, and 24 months after the induction course.
Study NCT00974818 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guerin (BCG)
Description: Patients randomized to this group will receive six weekly cycles of 81 mg of intravesical BCG (dissolved in a total volume of 53 mL of diluent and saline). Patients will receive three weekly cycles of 27 mg of intravesical BCG (dissolved in a total volume of 53 mL of diluent and saline) 3, 6, 12, 18, and 24 months after the induction course.
Study NCT00198770 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary substitution to assess level of caloric compensation
Description: Mushrooms substituted for meat in dishes
Study NCT02735928 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin
Description: After insufflation of a 12 mmHg of capnoperitoneum at 37 °C, two balloon trocars will be placed. Parietal biopsies will be taken and ascites (\< 500cc) will be removed. A nebulizer will be connected to a high-pressure injector and will be inserted into the abdomen through a trocar. A pressurized aerosol containing cisplatin at a dose of 10.5 mg/m2 body surface in 150 ml NaCl 0.9 % followed by doxorubicin at a dose of 2.1 mg/m2 body surface in a 50 ml NaCl 0.9% solution will be applied via a nebulizer immediately. Then, the system will be kept in steady-state for 30 min (i.e.: application time).
Study NCT00142090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% Hypertonic saline
Study NCT00142090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study NCT03774810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem tartrate
Description: Zolpidem Tartrate, 5mg for men older than 60 and women of all ages. 10 mg for men younger than 60.
Study NCT05471284 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proximal
Description: The first factor tested framing of the near, proximal threat of continued smoking.
Study NCT05471284 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distal
Description: The first factor tested framing of the long-term, distal threat of continued smoking.
Study NCT05471284 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cost
Description: Cost framework measures the response efficacy to quitting smoking by displaying costs of continued smoking.
Study NCT05471284 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Benefit
Description: Benefit framework measures the response efficacy to quitting smoking by displaying benefits of quitting.
Study NCT05471284 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss
Description: The third factor tested framing of the response efficacy of participating in a cessation study by utilizing loss of not participating in a smoking cessation.
Study NCT00225745 — intervention group
Intervention type: PROCEDURE
Intervention: Blood draw
Description: One blood draw prior to first treatment
Study NCT02690272 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychic processes
Description: Quantitative and qualitative aprroche of the psychic process
Study NCT01747356 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resolute stent treatment
Description: A well known coronary stent system that is produced by Medtronic Company and is also recommended by FDA for treating diabetic coronary lesion.
Study NCT00672568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4975 - Highly purified capsaicin
Description: Solution, 0.5 mg, single dose, injection
Study NCT00672568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4975 - Highly purified capsaicin
Description: Solution, 0.75 mg, single dose, injection
Study NCT00672568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4975 - Highly purified capsaicin
Description: Solution, 0.1 mg, Single dose, injection
Study NCT00672568 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution, single dose, injection
Study NCT01168921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Starting dose 75 mg by mouth (PO) daily for 28 day cycle
Study NCT00908271 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dapagliflozin
Description: Tablet and IV solution, Oral and IV, 10 mg po and 100 µg IV, Single oral dose followed by a single IV dose (IV dose administered at 1h after oral dose), 1 day
Study NCT06047639 — intervention group
Intervention type: DEVICE
Intervention: Bone-anchored hearing implants
Description: surgically placed hearing device
Study NCT01173315 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin and mineral supplementation
Description: Group MV: Zinc sulfate and Magnesium oxide (providing 10 mg Zn and 125 mg Mg) and vitamin C (100 mg) and vitamin E (100 mg); Group MVB: both of the above mineral and vitamin supplements plus vitamin B1 (5 mg), vitamin B2 (5 mg), vitamin B6 (5 mg), biotin (50 µg), vitamin B12 (5 µg) and folic acid (0.5 mg); Group P: starch (placebo).
Study NCT01173315 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vitamin and mineral supplementation
Description: Group MV: Zinc sulfate and Magnesium oxide (providing 10 mg Zn and 125 mg Mg) and vitamin C (100 mg) and vitamin E (100 mg); Group MVB: both of the above mineral and vitamin supplements plus vitamin B1 (5 mg), vitamin B2 (5 mg), vitamin B6 (5 mg), biotin (50 µg), vitamin B12 (5 µg) and folic acid (0.5 mg); Group P: starch (placebo).
Study NCT01388855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Subjects receive cholecalciferol 20,000 IU daily for 30 days followed by 20,000 IU once weekly for 8 weeks.
Study NCT01388855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pills made to look like vitamin D but have no medication in them
Study NCT00402792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone/Acetaminophen Extended-Release
Description: 1 tablet q 12 hours
Study NCT00402792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone/Acetaminophen Extended Release
Description: 2 tablets q 12 hours
Study NCT00402792 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets q 12 hours
Study NCT01912950 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prowave LX IPL
Study NCT00719160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: esomeprazole
Description: 2 Interventions with esomeprazole 20 mg twice a day for 9 days vs. a placebo for 9 days while on a high protein diet
Study NCT05471284 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gain
Description: The third factor tested framing of the response efficacy of participating in a cessation study by utilizing gain of participating in a smoking cessation.
Study NCT05471284 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Does not include any of the three message factors.
Study NCT00719160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole
Description: 2 Interventions with esomeprazole 20 mg twice a day for 9 days vs. a placebo for 9 days while on a high protein diet
Study NCT00719160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 20 mg twice a day for 9 days
Study NCT00719160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo 20 mg twice a day for 9 days
Study NCT00971867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Solution, I.V., 100 mg/m2 Weekly for 6 of 7 weeks, Until disease progression or unacceptable toxicity became apparent
Study NCT03207191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F16IL2
Description: F16IL2 dose escalation with provisional doses of 10, 20 and 30 Mio IU on Day 1, 8, 15 and 22 of each cycle through a rate-controlled intravenous infusion of 3 hours
Study NCT03207191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836858
Description: BI 836858 dose escalation with provisional doses of 10, 20, 40, 80 and 160 mg on days 3, 10, 17 and 24 of each cycle through a rate-controlled intravenous infusion up to 5 hours
Study NCT01519011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral azacitidine
Description: oral azacitidine 300-mg once daily for 3 total doses with two 150-mg tablets (fasted and fed) or three 100-mg tablets (fasted).
Study NCT01519011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral azacitidine
Description: 300-mg (three 100-mg tablets) once daily for 21 days of a 28-day cycle.